Effect of Key Baseline Disease Characteristics on Aflibercept 8 mg Dosing Interval Extension
Justus G. Garweg, Varun Chaudhary, Xin Zhang, Sérgio Leal et autres
OBJECTIVE: Post hoc analysis of the PULSAR phase 3 trial (NCT04423718) to determine whether dosing interval outcomes were associated with key baseline disease characteristics. DESIGN: Exploratory post hoc analysis of PULSAR, a 96-week, double-masked, active-controlled, randomized clinical trial in patients with treatment-naïve …
ch, ca, de, es, it, ar, au, us, at, bg, br, cn, sk, cz, ee, fr, ge, hu, il (code pays fourni par la source)
0 citations
Ophthalmology Retina